Results 81 to 90 of about 4,535 (170)

A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

open access: yeseLife
Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients.
Zhanwei Du   +8 more
doaj   +1 more source

Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis

open access: yesJournal of Infection in Developing Countries
Introduction: Paxlovid (nirmatrelvir/ritonavir) is a new oral antiviral drug that is used for coronavirus disease 2019 (COVID-19) and is administered to patients with mild to moderate disease for five consecutive days.
Yu Wang   +5 more
doaj   +1 more source

Paxlovid Awareness, Reporting Bias. [PDF]

open access: yesHealth affairs (Project Hope)
Widera, Eric, Lee, Todd C, Prasad, Vinay
openaire   +4 more sources

Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. [PDF]

open access: yesPharmaceuticals (Basel)
Zhu X   +8 more
europepmc   +1 more source

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid

open access: yesKidney International Reports, 2022
Philipponnet, Carole   +4 more
openaire   +2 more sources

Cardiovascular Outcomes in COVID-19 Patients Treated with Paxlovid: A Multicenter Retrospective Study. [PDF]

open access: yesActa Cardiol Sin
Chen WL   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy